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Abstract 
The Reduced folate carrier (Rfc1; Slc19a1)
mediated  transport  of  reduced  folates  and
antifolate drugs such as methotrexate (MTX)
play an essential role in physiological folate
homeostasis  and  MTX  cancer  chemotherapy.
As no systematic reports are as yet available
correlating Rfc1 gene expression and protein
levels  in  all  tissues  crucial  for  folate  and
antifolate uptake, storage or elimination, we
investigated  gene  and  protein  expression  of
rat  Rfc1  (rRfc1)  in  selected  tissues.  This
included the generation of a specific anti-rRfc1
antibody. Rabbits were immunised with isolat-
ed rRfc1 peptides producing specific anti-rRfc1
antiserum targeted to the intracellular C-ter-
minus of the carrier. Using RT-PCR analysis,
high rRfc1 transcript levels were detected in
colon,  kidney,  brain,  thymus,  and  spleen.
Moderate rRfc1 gene expression was observed
in small intestine, liver, bone marrow, lung,
and testes whereas transcript levels were neg-
ligible in heart, skeletal muscle or leukocytes.
Immunohistochemical  analyses  revealed
strong carrier expression in the apical mem-
brane of tunica mucosa epithelial cells of small
intestine and colon, in the brush-border mem-
brane of choroid plexus epithelial cells or in
endothelial cells of small vessels in brain and
heart.  Additionally,  high  rRfc1  protein  levels
were localized in the basolateral membrane of
renal  tubular  epithelial  cells,  in  the  plasma
membrane of periportal hepatocytes, and ser-
toli  cells  of  the  testes.  Taken  together,  our
results demonstrated that rRfc1 is expressed
almost ubiquitously but to very different levels.
The predominant tissue distribution supports
the essential role of Rfc1 in physiological folate
homeostasis. Moreover, our results may con-
tribute to understand antifolate pharmacoki-
netics and selected organ toxicity associated
with MTX chemotherapy.
Introduction
Reduced folate coenzymes like N5-methylte-
trahydrofolate are essential cofactors required
for  the  transfer  of  one-carbon  units  in  the
biosynthesis  of  purines  and  pyrimidines  as
well as in methylation reactions including the
formation of methionine from homocysteine.1
The  importance  of  folate  coenzymes  is  evi-
denced by the many clinical diseases associat-
ed with folate deficiency, such as neural tube
defects in neonates, cardiovascular complica-
tions, megaloblastic anaemia and carcinogen-
esis.1,2 As mammalian cells do not possess the
ability to synthesize folate derivatives de novo,
folate  intake  from  dietary  sources  is  vitally
required for normal cell growth and differenti-
ation.3
The  chemotherapeutic  drug  methotrexate
(MTX,  Amethopterin)  is  a  competitive
inhibitor of the folate-dependent enzyme dihy-
drofolate reductase resulting in inhibition of
DNA synthesis and cell death.4 MTX represents
an  essential  component  in  the  treatment  of
malignancies  including  leukemia,  lymphoma
or head and neck cancers,4,5 as well as autoim-
mune diseases such as rheumatoid arthritis.6
The Reduced Folate Carrier/Reduced folate
carrier  (RFC1/Rfc1;  SLC19A1/Slc19a1)  pro-
vides the major route for cellular uptake of nat-
ural  folate  compounds  and  antifolate  drugs
including MTX into liver, kidneys and other tis-
sues.5,7-9 Both  human  RFC110 and  rodent
Rfc17,11-13 cDNA clones have been isolated and
encode a carrier protein with 12 putative trans-
membrane domains (TMDs). Several studies
confirm that Rfc1 provides a low capacity but
high  affinity  transport  system  for  reduced
folates and MTX.5,14,15 As to the functional prop-
erties  of  this  carrier,  we14,16 and  other
researchers17-19 have shown that at acidic pH,
human  RFC1  and  Rfc1  from  rat  (rRfc1)  are
working mainly as folate transporters with no
obvious sodium-dependency, whereas at neu-
tral pH both carriers mediate uptake of MTX in
a  clearly  sodium-dependent  and  folic  acid-
insensitive manner. It has therefore been con-
cluded  that  human  RFC1  and  rRfc1  are
orthologs.16 Additionally,  the  mRNA  variant
Rfc2  resulting  from  alternative  splicing  has
been previously described.7,20 The Rfc2 protein
was predicted to contain 7 TMDs.20
Despite the substantial role of this carrier in
folate  homeostasis  and  MTX  cancer
chemotherapy, comparatively little information
is as yet available on the distribution and sub-
cellular  localisation  of  RFC1/Rfc1  in  mam-
malian  tissues.  Previous  gene  expression
studies  demonstrated  that  RFC1  transcripts
are expressed ubiquitously but to different lev-
els  in  all  tissues  and  a  number  of  tumour
cells.5,13 Rfc1  protein  expression  was  only
assessed in selected murine tissues such as
small intestine.21 Moreover, there is only limit-
ed data on the subcellular distribution of this
carrier  protein.  Murine  Rfc1  (mRfc1)  was
detected  in  the  apical  membrane  of  small
intestine and colon as well as choroid plexus
and retina pigment epithelium.22 Additionally,
mRfc1 was localized to the basolateral surface
of renal tubular epithelial cells.21 Furthermore,
Rfc  was  detected  in  hepatocellular  plasma
membrane  as  well  as  in  jejunal  and  kidney
brush  border  membrane  vesicles  from
micropigs.23 However,  comparable  studies  to
the  immunohistochemical  determination  of
hRFC1  or  rRfc1  are  not  available.  Moreover,
there are currently no systematic reports cor-
relating Rfc1 gene and protein expression in
all tissues of particular relevance for folate and
antifolate  uptake,  storage  and  elimination.
Particularly,  the  expression  of  Rfc1  protein
from rat (rRFC1), a common animal model for
man, by immunological methods has not been
described up to now. Therefore, the aim of this
study was to systematically investigate rRFC1
gene  expression  and  protein  levels  and  in
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selected rat tissues. Here, the determination of
subcellular carrier localization was of particu-
lar  interest  in  order  to  improve  the  under-
standing of the role of rRfc1 in the vectorial
transport of folate analogues across cell plas-
ma membranes. 
Materials and Methods
Reagents 
All chemicals including media and supplements
were obtained from Sigma-Aldrich (Deisenhofen,
Germany) unless otherwise stated.
Cell culture and tissues
Madin-Darby canine kidney (MDCK) type II
cells stably expressing rRfc1 tagged with a C-
terminal  HA  epitope  (MDCK-rRfc1-HA)  were
generated  as  previously  described.8 MDCK-
rRfc1-HA  and  wild-type  MDCK  II  cells  were
maintained in Earle’s modified Eagle’s medi-
um (MEM; PAA, Coelbe, Germany) containing
10% (v/v) fetal calf serum (Gibco, Karlsruhe,
Germany) and 1X non-essential amino acids as
previously delineated.8
Selected tissues were obtained from male
Sprague-Dawley  rats  (300  g).  Animals  were
euthanized  by  asphyxiation  with  CO2 and
selected organs were removed. All tissues were
snap frozen in liquid nitrogen and subsequent-
ly stored at -80°C. These procedures were con-
ducted  in  the  central  animal  facility  of  the
Medical Faculty of the University of Leipzig,
according to institutional guidelines for ethi-
cal care and use of animals for experimental
and other scientific purposes.
Construction of fusion proteins and
production of rRfc1 specific peptides
The predicted structure of the rRfc1 protein
has  been  previously  described.7 Highly  anti-
genic regions in the rRfc1 protein sequence
were identified by determination of the anti-
genic  index24 using  Protean  5.06  (DNAStar
software, Inc., Madison, WI, USA). The select-
ed  rRfc1  peptide  sequence  at  amino  acid
residues 445-512 comprising the intracellular
C-terminus  of  the  carrier  was  amplified  by
PCR using 1/50 of cDNA (pRK-MTX1) that has
been previously described.8 The PCR product
denoted  intracellular  domain  7  (ID7)  was
cloned  into  the  expression  vector  pET-41a
(Novagen,  Inc.,  Madison,  WI,  USA)  via
EcoRI/HindIII (NEB, Ipswich, MA, USA). The
pET-41a vector contains a glutathione-S-trans-
ferase (gst) and histidine (His)6 gene as fusion
tags to aid in purification steps. The resulting
pET-ID7 vector was confirmed by sequencing
and  restriction  analysis,  respectively.  After
expression  of  the  pET-ID7  fusion  protein  in
IPTG  (0.4  mM;  Roth,  Karlsruhe,  Germany)-
induced  E.  coli Rosetta  cells  (Novagen)  the
bacteria  were  lysed  with  20  mg/g  lysozyme
including DNase (250 U/g). Affinity purifica-
tion of soluble His6-tagged pET-ID7 fusion pro-
teins was performed using Ni-NTA His-Bind®
Resin  (Novagen).  Subsequently,  fusion  pro-
teins were eluted with imidazole (300 mM) in
elution buffer (0.5 M NaCl, 20 mM Tris-HCl, pH
7.9).  The  purity  of  protein  was  assessed  by
SDS-PAGE  (16%)  and  Coomassie  staining
(Coomassie  Brilliant  Blue  R-250,  Roth,
Karlsruhe, Germany). The amount of pET-ID7
protein was determined by saturation of a His-
Bind® Column  (Novagen)  with  a  theoretical
capacity of 20 mg protein. Then, GST- and His-
tags were cleaved from the rRfc1 specific pep-
tide  (RSP)  by  means  of  enterokinase 
(30 mg/mg fusion protein) over 6 h in dialysis
buffer (200 mM NaCl, 20 mM Tris-HCl, 200 mM
imidazole pH 8.0). To obtain RSP as the pure
antigen, samples were filtrated (3000 ﾥ g) for
2  h  through  centrifugal  concentrators
(Centriplus  YM-50,  Millipore,  Schwalbach,
Germany).  Concentrated  RSP  was  stored  at
4°C until immunization.
Immunization and generation of
polyclonal Rfc1 antiserum
In this study, three New Zealand White rab-
bits (1800-2000 g, Charles River laboratories,
Kiblegg, Germany) were immunised with RSP
ID7  to  obtain  specific  polyclonal  Rfc1  anti-
serum. Animals were housed under standard
conditions in the central animal facility of the
Medical  Faculty  of  the  University  of  Leipzig
according to institutional guidelines for ethi-
cal care and use of animals for experimental
and other scientific purposes.
The RSP ID7 (0.4-1 mg/mL) was emulsified
with an equal volume of Freund’s adjuvant, and
1 mL containing 0.2-0.5 mg ID7 was injected
into 10 dorsal sites of rabbits. Animals received
a booster injection with 0.2-0.5 mg ID7 emulsi-
fied in Freund’s incomplete adjuvant after 2, 4,
6,  and  8  weeks  after  primary  immunization.
Rabbits were bled before primary immunization
(preimmune) as well as 4, 6, and 8 weeks after
immunization. Subsequently, affinity purifica-
tion of ID7 antibody was performed using CRBr
- activated agarose. Initially, a column exhibit-
ing bound control vector pET-41 was used to
remove  unspecific  antibodies  against  fusion
protein without rRfc1. In a second purification
step, ID7 antiserum was concentrated using a
column  to  which  the  corresponding  antigen
pET-ID7 was covalently linked. Elution of puri-
fied antiserum was achieved using neutralisa-
tion buffer (1 M Tris-HCl, pH 9). Purified and
concentrated ID7 antiserum was stored at 4°C
after addition of NaN3 (10 mM).
RT-PCR
Selected tissues were obtained from male
Sprague-Dawley  (SD)  rats  of  approximately
300 g weight. Total RNA was prepared from 20
mg of liver, kidney, spleen, and thymus or 30
mg of other selected tissues using the RNeasy
Mini  system  (Qiagen,  Hilden,  Germany).
Purification  of  total  RNA  was  achieved  by
digestion with DNase (15 U; Qiagen, Hilden,
Germany).  Contamination  with  contractile
proteins of RNA samples from skeletal or car-
diac muscle fibres were removed by incuba-
tion  with  proteinase  k  for  10  min  (55°C).
Reverse transcription into cDNA using 1 µg
total RNA was performed under standard con-
ditions  employing  the  Omniscricpt  RT  kit
(Qiagen)  with  4  U  of  reverse  transcriptase
and 1 µM oligo(dT16-) primer (MWG Biotech,
Ebersberg, Germany). Semiquantitative PCR
of 1 µL cDNA was carried out using the PCR-
Master-Mix  S  (Peqlab,  Erlangen,  Germany)
with  1.25  U  taq-DNA-polymerase,  0.25  mM
dNTPs, 0.4 pmol of rRfc1 specific sense (5’-
CCAGAGCCCAGGAAACTG-3’)  and  antisense
(5’-GCAATCTGAAAAGTGGCAATG-3’)  primers
or  specific  b-actin  primers  as  previously
delineated.25 PCR  amplification  was  per-
formed over 40 cycles for rRfc1 and 30 cycles
for b-actin with an initial denaturation step
of 30 sec at 94°C followed by annealing and
extension for 30 sec at 58°C and 72°C, respec-
tively,  A  final  extension  was  carried  out  at
72°C  for  3  min.  The  PCR  products  were
analysed by agarose gel electrophoresis with
regard to size of the expected fragment. ß-
actin was used as positive control and ampli-
fication  of  genomic  DNA  was  excluded  by
omitting reverse transcriptase.
SDS-PAGE and immunoblotting
MDCK II cells expressing rRfc1-HA or wild-
type MDCK II cells were cultured until subcon-
fluency. Cells (15ﾥ106) were washed with ice-
cold  PBS  und  incubated  in  Laemmli  lysis
buffer26 without  b-mercaptoethanol.  Proteins
were separated on SDS/10% polyacrylamide gel
and  blotted  onto  polyvinylidene  fluoride
(PVDF)  membrane.  Unspecific  binding  was
blocked with 3% BSA in TBS-Tween (20 mM
Tris-HCl,  pH  7.5,  150  mM  NaCl,  0.05%  (v/v)
Tween 20) overnight (4°C). Membranes were
probed with rabbit anti rRfc1 antiserum (ID7;
1:500) for 1 h (rt) following visualization with
AP-conjugated  goat  anti-rabbit  IgG  (1:2000,
Dako  Cytomation,  Hamburg,  Germany).
Protein  samples  of  native  HPCT-1E3  cells
probed with anti- rRfc1 antiserum served as a
negative control.
Immunofluorescence
For  indirect  immunolocalization  of  rRfc1,
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MDCK-rRfc1-HA  cells  were  cultured  on  glass
cover  slips.  Cells  were  fixed  with  2%  (w/v)
paraformaldehyde (10 min at 20°C) and perme-
abilised with 0.1% (v/v) Triton X-100. Unspecific
binding was blocked with 3% (v/v) BSA in phos-
phate-buffered saline (PBS). Nuclear staining
was achieved by addition of DAPI (0.5 µg/mL).
Cells were incubated with rabbit anti rRfc1 anti-
serum (ID7; 1:500) at 4°C overnight in 3% (v/v)
BSA in PBS. Visualisation of rRfc1 was achieved
with FITC-conjugated anti-rabbit IgG (1:200) for
1 h at room temperature. Finally, the specimens
were washed and mounted on slides. As a posi-
tive control, rRfc1-HA was detected with mouse
monoclonal  anti-HA  antibody  (HA-7;  1:200)
overnight at 4°C following visualization with R-
PE-conjugated goat anti-mouse IgG (1:200; Dako
Cytomation, Hamburg, Germany) for 1 h at room
temperature.  Control  experiments  were  per-
formed using wild-type MDCK II cells as well as
incubation of cells with rRfc1 antiserum in the
presence of pET-ID7 fusion protein (5 µg/mL).
Cells were viewed with a fluorescence micro-
scope (Olympus BX50, Hamburg, Germany). 
Immunohistochemistry
Selected organs were obtained from 2 male
Sprague-Dawley  (SD)  rats  of  approx.  300  g
weight. Cryostat sections (5-7 µm) were cut and
fixed  in  actone  (-20°C)  for  10  min.  Then,
cryosections  were  dried  at  room  temperature
(rt) for 10 min and washed in PBS for 15 min.
Immunohistochemistry on cryosections was per-
formed  using  a  modified  method  previously
described.21 In  brief,  endogenous  peroxidase
activity was quenched by incubation of slides
into  cold  0.03%  H2O2 on  ice  for  15  min.
Nonspecific binding was blocked with 3% (v/v)
BSA in PBS for 1 h (rt). Specific rRfc1 antiserum
was added at a 1:500 dilution for 72 h at 4°C.
Then, samples were rinsed 3 times with PBS
buffer for 10 min and incubated with HRP-conju-
gated  swine  anti-rabbit  secondary  antibody
(1:250; Dako Cytomation, Hamburg, Germany)
in blocking buffer overnight (4°C). Afterwards,
3,3’-  diaminobenzidine  (DAB)  substrate  solu-
tion  (1:50;  Dako  Cytomation,  Hamburg,
Germany) was added for 10 min. Then, the reac-
tion was stopped by several washing steps with
PBS, samples were counterstained with Mayer’s
hematoxylin and mounted in Fluor Save reagent
(Calbiochem,  Bad  Soden,  Germany).  Control
experiments were carried out by incubation of
samples with the preimmune serum. 
Results
Generation of rRfc1 specific pep-
tides for immunization
The structure of the rRfc1 protein with 12
predicted transmembrane domains has been
previously described.7 For the development of
specific  antiserum  directed  against  certain
peptide  sequences  of  Rfc1,  highly  antigenic
regions were selected simultaneously compris-
ing intra- or extracellular loops of the carrier
protein (Figure 1A) facilitating the use of the
antiserum for immunohistochemical studies.
Several  antigenic  peptide  sequences  within
the rRfc1 protein were identified by determi-
nation of the antigenic index (AI) (Figure 1B)
illustrated as positive values for certain pro-
tein  subdomains  (AI>0).  Highly  antigenic
regions with an AI of ≥1.5 were calculated for
intracellular localized amino acid residues 1-
27  denoted  as  ID1,  200-268  (ID4),  445-512
(ID7) as well as extracellular localized amino
acid residues 40-73 designated OD1 and amino
acid residues 403-428 (OD6) (Figure 1 A,B)
indicating a high antigenicity. 
Nucleotide sequences encoding these pep-
tide domains were amplified and cloned into
the  expression  vector  pET-41a  exhibiting  a
His6-tag to aid in purification steps resulting in
the  following  fusion  proteins:  pET-ID1,  pET-
ID4, pET-ID7 as well as pET-OD1 and pET-OD6.
As expected, fusion protein pET-ID7 exhibited
a molecular weight of 41.9 kDa (Figure 2 A, left
column).  After  cleavage  of  vector-associated
tags with proteinase K the specific rRfc1 ID7
peptide (10.5 kDa) comprising the intracellu-
lar  C-terminus  of  the  carrier  was  obtained
(Figure 2A, right column). Cleavage of other
selected fusion proteins resulted in the pro-
duction  of  the  following  rRfc1  peptides:  ID1
(6,2 kDa), ID4 (11 kDa), and OD1 (7.0 kDa)
(not shown).
Antigen reactivity and specificity of
rRfc1 antiserum
In  order  to  produce  specific  rRfc1  anti-
serum, rabbits were immunized by standard
procedures  with  the  above  mentioned  rRfc1
selective peptides. Specificity of the respective
antiserum was confirmed in MDCK cells stably
expressing rRfc1.8
Using Western blot analysis, a single strong
band was detected with ID7 antiserum at ~72
kDa (Figure 2 B) representing rRfc1.7 In con-
trast, no band could be observed in wild-type
MDCK cells lacking rRfc1 expression, indicating
that  this  antiserum  was  specific  for  rRfc1.
Moreover, Western blot analyses of MDCK-rRfc1-
HA  cells  using  anti-HA  antibody  equally  pro-
duced a band at ~72 kDa (not shown), validating
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Figure 1. Determination of antigenic regions in the rRfc1 protein sequence. A, the struc-
ture of the rRfc1 protein with 12 predicted transmembrane domains was used to select
adequate protein domains for immunization. Suitable protein sequences are highlighted
in black comprising intracellular domains or extracellular localized domains. B, highly
antigenic regions in the rRfc1 protein sequence were identified by determination of the
antigenic index by Jameson-Wolf. The highly antigenic domain corresponding to amino
acid (aa) residues 445-512 comprising the intracellular C-terminus of the carrier (ID7)
was used to generate the polyclonal antiserum.[page 14] [European Journal of Histochemistry 2011; 55:e3]
the specificity of ID7 antiserum for rRfc1.
To further corroborate the specificity of rab-
bit rRfc1 ID7 antiserum, cells were simultane-
ously probed with ID7 antiserum and anti-HA
antibody and analysed by indirect immunofluo-
rescence.  Incubation  with  ID7  antiserum
(Figure 3 A) and anti-HA antibody (Figure 3 B)
resulted  in  a  strong  immunopositive  signal
localized to the plasma membrane of MDCK-
rRfc1-HA  cells.  Overlay  of  both  pictures
revealed,  that  subcellular  localization  of  both
staining was identical (Figure 3 C). In contrast,
no  staining  was  detected  in  wild-type  MDCK
cells (Figure 3 D). Moreover, the ID7-associated
immunopositive signal was abolished by con-
current  incubation  of  MDCK-rRfc1-HA  cells
with pET-ID7 fusion protein further approving
selectivity of the ID7 antibody (Figure 3 E). In
regard to the other selected rRfc1 peptides no
specific  carrier  signal  could  be  detected  in
Western  blot  or  immunocytochemical  studies
using MDCK-rRfc1-HA cells (not shown).
Gene expression of rRfc1 
To  determine  gene  expression  of  rRfc1  in
normal  rat  tissues,  we  performed  a  RT-PCR
analysis and compared the expression profile of
selected  organs.  In  this  study,  rRfc  specific
primers were used that also allow the detection
of the rRfc splicing variant rRfc2.20 As shown in
Figure 4, rRfc1 transcripts were detected in all
chosen organs. As to the carrier expression in
intestine,  our  results  show  higher  levels  of
rRfc1 mRNA in colon than in small intestine.
Moreover, there was a significant decrease in
carrier expression levels from proximal duode-
num to distal ileum within the small intestine.
Besides colon, a strong rRfc1 expression was
observed in kidney, brain, thymus, and spleen. A
moderate  signal  was  obtained  for  liver,  lung,
duodenum, jejunum, testis, and bone marrow.
In contrast, rRfc1 transcript levels in arteries as
well as in skeletal or cardiac muscle fibres were
near the detection limit. In a number of tissues
including kidney, brain, thymus, and spleen as
well as duodenum, colon and testis expression
of the rRfc splicing variant rRfc2 could also be
observed (Figure 4). With regard to the other
selected tissues exhibiting a moderate to weak
rRfc1  expression,  no  rRfc2  transcripts  were
detected may be due to the detection limit.                      
Tissue distribution and subcellular
localization of rRfc1 protein
In order to compare rRfc1 transcript levels
and  tissue  expression  with  the  distribution
pattern of Rfc1 protein, carrier localization was
investigated in selected rat tissues using spe-
cific anti-Rfc1 ID7 antiserum. 
In  a  variety  of  normal  rat  tissues,  strong
immunoreactivity  was  observed.  Prominent
staining was recovered in the gastrointestinal
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Figure 3. Specificity of ID7 antiserum against the C-terminus of Rfc1 from rat by indirect
immunofluorescence. MDCK-rRfc1-HA (A-C, E) or wild-type MDCK II cells (D) were
seeded on glass cover slips and cells were incubated with rabbit anti rRfc1 antiserum (ID7;
1:500) in the presence (E) or absence of pET-ID7 fusion protein (5 µg/mL) or with a spe-
cific anti-HA antibody (1:200, B). Colocalization of Rfc1 and Rfc1-HA protein results in
simultaneous fluorescence producing a yellow/orange signal (C). Cell nuclei (blue) were
visualized by means of DAPI (A, Rfc1 in green; B, Rfc1-HA in red; Magnification A-C, ×
100; D+E, ×40).
Figure 4. Rfc1 gene expression in selected rat tissues as assessed by RT-PCR analysis. Total
RNA was isolated from selected organs and used for RT-PCR analysis as described in the
Materials and Methods section. Sizes of expected Rfc1 (443 bp) or Rfc2 (645) transcripts
are indicated by arrows. RT-PCR of b-actin (138 bp) was carried out as positive control.
The RT-PCR analysis shown is representative of two independent experiments. 
Figure  2.  SDS-PAGE  analysis  of  Rfc1  specific  peptide  (RSP)  ID7.  A,  Equal  protein
amounts of pET-ID7 fusion protein (~42 kDa) or isolated RSP ID7 (~10.5 kDa) were sep-
arated on a SDS/16% polyacrylamide gel and proteins were detected by Coomassie blue
staining. B, Specificity of ID7 antiserum against the C-terminus of Rfc1 from rat by
Western blot analysis. Equal protein amounts of MDCK-rRfc1-HA (lane 1) or wild-type
MDCK II (lane 2) cells were separated on a SDS/10% polyacrylamide gel. Rfc1 was detect-
ed by ID7 antibody and is apparent at ~72 kDa (→). [European Journal of Histochemistry 2011; 55:e3] [page 15]
tract, with a strong immunopositive signal in
duodenum and colon (Figure 5 A) while stain-
ing levels were moderate in jejunum (Figure 5
B) and ileum (not shown). In kidney, high lev-
els  of  immunohistochemical  staining  were
detected in proximal and distal tubular epithe-
lial cells (Figure 5 C) whereas no signal was
recovered in the gomeruli (not shown) or the
collecting duct (Figure 5 C). Moderate staining
for Rfc1 was observed in liver (Figure 5 D).
Here, Rfc1 immunoreactivity was particularly
determined in the periportal zone of hepatic
lobules located near the portal triade. In con-
trast, no carrier signal was detected in the cen-
trilobular zone around the central lobular vein.
Treatment of brain tissues with anti-Rfc1 ID7
antiserum  resulted  in  a  strong  staining  in
choroid  plexus  epithelial  cells  (Figure  6  A).
Additionally,  Rfc1  immunoreactivity  was
observed in capillary endothelial cells, which
represent the blood-brain barrier (Figure 6 B)
and  cells  composing  the  pia  mater  (not
shown). In regard to skeletal muscle, positive
Rfc1 signals were only present in the perimysi-
um likely associated with small blood vessels
(Figure  6  C).  Similarly,  heart  tissue  probed
with  Rfc1  antiserum  only  showed  a  positive
signal  in  endothelial  cells  of  small  vessels
(Figure  6  D).  In  skeletal  or  cardiac  muscle
cells, no staining was observed. Additionally,
no  specific  Rfc1  immunoreactivity  could  be
established  in  lung,  i.e.,  alveolar  epithelial
cells,  bronchus  associated  lymphoid  tissue
(BALT)  associated  cells  (not  shown).
Furthermore, significant staining could not be
observed in leukocytes or bone marrow (not
shown). In general, no immunoreactivity was
detected in samples probed with preimmune
serum (not shown).
Using  immunohistochemical  analyses,  we
further aimed at determining the subcellular
localization of rRfc1 protein in selected normal
rat tissues. In the gastrointestinal tract, rRfc1
immunoreactivity was observed in the apical
membrane of jejunum (Figure 5 B). Moreover,
our results indicate subcellular localization of
Rfc1 at the apical membrane of colon (Figure 5
A).  Additionally,  rRfc1  was  detected  on  the
brush-border  membrane  of  choroid  plexus
epithelial cells facing the cerebrospinal fluid
while no positive signal was recovered in the
basolateral membrane adjacent to brain capil-
laries (Figure 6 A). High levels of Rfc1 protein
were  also  found  in  the  apical  membrane  of
endothelial cells of small vessels in heart tis-
sue (Figure 6 D). Similarly, our results indi-
cate subcellular localization of Rfc1 at the api-
cal membrane of endothelial cells composing
the blood-brain barrier (Figure 6 B) as well as
of  small  vessels  in  skeletal  muscle  tissue
(Figure 6C). In contrast, Rfc1 was observed in
the  basolateral  membrane  of  renal  tubular
epithelial cells while no immunoreactivity was
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Figure 5. Immunolocalization of Rfc1 in rat tissues by specific anti Rfc1 ID7 antiserum.
A, Rfc1 immunoreactivity was detected in tunica mucosa cells (arrow) of colon (4×) and
B, at the apical membrane (arrow) of jejunal epithelial cells (100×). C, expression of Rfc1
in the basolateral membrane of renal tubule cells (20×), not collecting duct; insert, renal
tubule, (100×). D, in liver Rfc1 was particularly found in the plasma membrane of hepa-
tocytes in the periportal zone of hepatic lobules located near the portal triade, not the cen-
trilobular zone (10×); insert, Rfc1 was localized to the basolateral membrane (black arrow-
head) while the amount of Rfc1 in the apical membrane (white arrowhead) was negligible,
(100×). CD, collecting duct; T, renal tubule; CV, central vein; LT, liver triade.
Figure 6. Immunohistochemical analysis of rat tissues exposed to specific anti Rfc1 ID7
antiserum. A, choroid plexus, Rfc1 is localized at the apical membrane of choroid plexus
epithelial cells (black arrowhead) not at the basolateral membrane (white arrowhead)
(100×). B, Rfc1 immunoreactivity in endothelial cells of small brain vessels, not pyramid
cells (black arrowhead) (100×). C. positive Rfc1 signals were present in the perimysium of
skeletal muscle fibres (20×). D, heart, Rfc1 localized to the apical membrane of endothe-
lial cells of small vessels (black arrowhead), not cardiac muscle cells (20×).[page 16] [European Journal of Histochemistry 2011; 55:e3]
apparent  in  the  apical  membrane  or  in  the
cytosol (Figure 5C). Moreover, cellular distri-
bution of Rfc1 was predominantly apparent at
the basolateral plasma membrane of periportal
hepatocytes  while  no  cellular  staining  was
determined in hepatocytes of the centrilobular
zone (Figure 5 D). In regard to other tissues
examined,  a  precise  allocation  of  Rfc1
immunoreactivity to subcellular compartments
was not possible.
Discussion
Reduced folate coenzymes like N5-methylte-
trahydrofolate  are  essential  cofactors  vitally
required  for  cell  growth  and  differentiation.
Generally, uptake of folates into mammalian
cells can be mediated by three transport sys-
tems: the Reduced folate carrier (Rfc1),3 the
family of folate receptors (FR),3 and the pro-
ton-coupled  folate  transporter  (PCFT/
SLC46A1).27
With  exception  of  kidney  normal  tissues
express  low  to  negligible  levels  of  FR.28
Interestingly,  porcine  FR  protein  has  been
recently  detected  in  hepatocellular  plasma
membranes as well as in kidney but not jejunal
brush-border membranes.29 However, in man
and rodent FR is absent in both liver and intes-
tine.30 Expression  of  PCFT  was  found  in
human (hPCFT) and murine (mPCFT) small
intestine,  kidney,  liver,  placenta,  retina,  and
brain.30 No information is as yet available on
PCFT  expression  in  rat  normal  tissues.
hPCFT/mPCFT and hRFC/mRfc are both local-
ized at the apical brush-border membrane and
contribute  to  folate  absorption  at  acidic  pH
though recent data indicate that PCFT repre-
sents  the  main  intestinal  folate  uptake  sys-
tem.30,31 However, both transporters are upreg-
ulated in small intestine in mice fed a folate-
deficient  diet.30 In  rat  small  intestine,  PCFT
seems to play a minor role in folate absorption
as siRNA to rRfc almost completely abolished
folate  uptake  at  pH  5.5  in  PCFT-expressing
(Halwachs  et  al.,  unpublished  data)  rat-
derived  intestinal  epithelial  IEC-6  cells.9
Moreover, PCFT is generally negligible in sys-
temic delivery of folate at neutral pH as this
carrier only displays optimal transport activity
at acidic pH.32 At neutral pH, Rfc1 is therefore
regarded as the predominant route for mem-
brane  transport  of  reduced  folates  in  mam-
malian tissues. Besides, Rfc1 mediates cellular
uptake of antifolate drugs such as methotrex-
ate (MTX).5 As the loss of transport function
results in MTX tumour cell resistance,5 Rfc1
uptake activity represents the major determi-
nant of the clinical efficacy of MTX chemother-
apy. 
Although  gene  expression  studies  demon-
strated that human and murine RFC1/Rfc1 tran-
scripts are expressed ubiquitously but to differ-
ent levels in all tissues.5,13 Rfc1 protein expres-
sion was only assessed in selected murine tis-
sues  such  as  small  intestine.21 Furthermore,
there is only limited data on the subcellular dis-
tribution of this carrier protein. With regard to
rat,  a  common  animal  model  for  man,  no
detailed information on Rfc1 gene expression
and protein levels is as yet available. In order to
better  understand  the  role  of  Rfc1  in  folate
homeostasis and MTX cytotoxicity, we systemat-
ically examined Rfc1 gene and protein expres-
sion as well as subcellular carrier localization in
selected normal tissues from rat. 
Our results demonstrate that Rfc1 mRNA is
expressed in all selected rat tissues but the
Rfc1 transcript level varies from tissue to tis-
sue. In line with results regarding human33
and murine34 Rfc1 gene expression, the high-
est  mRNA  levels  were  determined  in  colon,
kidney, brain, and lymphatic organs including
spleen  and  thymus.  In  contrast  to  human
RFC1,33 rRfc1  gene  expression  in  liver  and
peripheral  blood  leucocytes  was  less  pro-
nounced  while  carrier  expression  for  other
tissues examined were in the same range as
shown  for  human  or  murine  Rfc1.33,34
Differences in hepacellular or leucocyte Rfc1
gene expression may reflect different levels of
transcription  factors  due  to  species-specific
alternate signalling pathways.5 Additionally, in
tissues  demonstrating  high  rRfc1  transcript
levels  including  kidney  or  lymphatic  organs
the mRNA variant Rfc2 resulting from alterna-
tive  splicing7,20 could  also  be  detected.
However,  it  is  unlikely  that  this  alternative
transcript are directly involved in membrane
transport of folate derivates as the resulting
protein is retained in the cytosol and subse-
quently degraded as shown for Rfc2 from kid-
ney.35
Previous  studies  indicate  that  different
transcription factors including members of the
Sp family or usage of alternate promoters/non-
coding exons play an important role in the tis-
sue-specific Rfc1 expression and function.5 As
organs  exhibiting  high  cell  proliferation
including  bone  marrow  or  testes  showed
strong Rfc1 gene expression while in differen-
tiated tissues such as cardiac muscle cells or
lung only low Rfc1 signals were detected, the
specific Rfc1 distribution pattern may reflect
different requirements for folates. Accordingly,
only low folate levels were observed in lung
and skeletal or cardiac muscle cells36 suggest-
ing a minor role for Rfc1-mediated transport in
these tissues. 
In this study, tissue distribution of Rfc1 pro-
tein was investigated using a newly synthe-
sized  rabbit  rRfc1  antiserum  termed  ID7
directed against the C-terminus of the carrier
protein. Antibody specificity was confirmed in
MDCK II cells stably expressing rRfc1-HA by
application of pET-ID7 fusion protein as a spe-
cific  blocking  peptide.  Furthermore,  our
results  derived  from  Western  blot  and
immunocytochemical  analyses  using  Rfc1
antiserum demonstrated an approximately 72-
kDa protein localized to the plasma membrane
of  MDCK-rRfc1-HA  cells  similar  to  previous
findings by Kneuer et al.,8 who used a specific
anti-HA antibody for rRfc1 detection. Similarly,
a ~70 kDa protein was also detected in various
human  tumour  cell  lines  using  hRFC  anti-
serum.
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Our results argued for subcellular localiza-
tion of rRfc1 at the apical brush-border mem-
brane  of  jejunum  and  colon.  Importance  of
these results are illustrated by the fact that
mammalian cells cannot synthesize folates de
novo necessitates  carrier-mediated  internal-
ization  of  dietary  folates  across  the  apical
intestinal membrane including Rfc1 in order
to  maintain  folate  homeostasis  and  thereby
ensure cell growth and survival.3 The critical
role of Rfc1 in folate absorption is supported by
the fact that dietary folate deficiency leads to a
marked upregulation in Rfc1 expression and
intestinal  folate  uptake.34,38 Moreover,  Rfc1
expression  correlates  with  the  content  of
dietary or bacterial synthesized folate in duo-
denum and colon, respectively. Besides, promi-
nent expression of Rfc1 may determine anti-
tumour activity of antifolate drugs including
MTX and contribute to common intestinal cyto-
toxicity after oral MTX application associated
with villos atrophy.39
In contrast to intestine, Rfc1 was localized
to the basolateral membrane of renal tubular
epithelial cells. Similar results were obtained
for murine Rfc1.21 The observed strong carrier
expression may provide an indication of the
involvement  of  Rfc1  in  folate  reabsorption
from the glomerular filtrate probably in concert
with folate receptors found in the apical tubu-
lar membrane.3,28 This hypothesis is corrobo-
rated by previous findings showing a signifi-
cant ethanol-induced decrease in renal folate
uptake as a result of reduced folate receptor as
well as Rfc1 expression in the apical and baso-
lateral  membrane,  respectively.40 Likewise,
MTX is primarily eliminated by renal excre-
tion4and MTX chemotherapy is often related to
renal  dysfunction  resulting  in  delayed  drug
elimination  and  enhanced  MTX  toxicity.41
Precipitation of MTX and its metabolites in the
renal tubules represents a major cause of MTX
nephrotoxicity.41 As  previous  studies  demon-
strated a significant increase in MTX cytotoxi-
city in Rfc1-expressing renal MDCK cells com-
pared to Rfc1-lacking wild-type cells,8 a direct
involvement of Rfc1 in MTX nephrotoxocity is
also very likely. 
Rfc1  was  predominantly  apparent  at  the
sinusoidal  membrane  of  periportal  hepato-
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cytes. The liver represents the main storage
side for folate and provides redistribution of
reduced folate cofactors to peripheral tissues
via  the  enterohepatic  cycle.42 As  important
metabolic  liver  functions  take  place  in  the
periportal zone of the liver lobule, Rfc1-medi-
ated internalization and subsequent formation
of  folate  polyglutamates  as  the  intracellular
storage form is very likely. Formation of MTX
polyglutamates  is  also  responsible  for  drug-
induced  hepatotoxicity.  In  line  with  the
observed  periportal  carrier  localization,  MTX
therapy resulted in periportal liver fibrosis.
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In  accordance  to  Rfc1  gene  expression,
prominent apical staining of rRfc1 protein was
observed in the apical membrane of choroid
plexus  (CP)  epithelial  cells  composing  the
blood-CSF-barrier (BCB). This expression pat-
tern reflects the essential role of Rfc1 in cere-
bral  folate  homeostasis  as  Rfc1  mediates
secretion of reduced folates into CSF resulting
in  four  times  the  plasma  folate  concentra-
tion.44 Clinical significance of Rfc1 expression
in BCB is illustrated by previous studies that
have linked folate deficiency to neurologic dis-
orders such as depression as reduced levels of
a  5-hydroxytryptamine  metabolite  were
restored to normal in individuals after folate
supplementation.45 Conversely, MTX is elimi-
nated from CSF into blood via uptake through
Rfc1 and Mrp-mediated extrusion of the drug.44
Neurotoxicity  is  a  common  complication  in
patients who receive systemic or intrathecal
MTX therapy resulting in neurologic disorders
such as seizures.4 This may be due to abnor-
mal  MTX  efflux  across  the  BCB  as  formerly
suggested  for  patients  with  central  nervous
system leukemia.46
In  conclusion,  our  results  show  that
although the rRfc1 is expressed ubiquitously,
the intensity of its expression varies strongly.
The prevalent tissue distribution of the carrier
supports the pivotal role of Rfc1 uptake activi-
ty  in  folate  homeostasis  reflecting  strong
folate requirements of high proliferating tis-
sues or specialized tissue functions as shown
for  various  tissues  involving  reduced  folate
coenzymes. As a consequence, impairment of
Rfc1-mediated folate transport results in dis-
ruption  of  physiological  folate  homeostasis
and thereby enhances the existing widespread
latent folate deficiency, due to an inadequate
dietary  folate  intake.47-49 Folate  deficiency
finally increases the risk of neural tube defects
in  neonates,  cardiovascular  diseases,2 and
cancer.50,51
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